Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[2].
[1]. Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use. Patent WO2019173911A1.
[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.